

Form PTO-1449				ATTY DOCKET NO. 2801-0159P		APPLICATION NO. 09/495,861	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				APPLICANT Martin J. PAGE et al.			
				FILING DATE February 2, 2000		GROUP 1644	
U.S. PATENT DOCUMENTS							
Examiner Initials	ID	Document Number	Year	Name	Class	SubClass	Filing Date
<div style="font-size: 2em; font-family: cursive;">P</div>		USP 5605689	1997	Ammann	2/25/97		
		USP 4399216	1983	Axel et al.	8/16/93		
		USP 4456748	1984	Goeddel	6/26/84		
		USP 4816567	1989	Cabilly et al.	3/23/89		
		USP 5081235	1992	Shively et al.	11/14/92		
		USP 5098833	1992	Lasky et al.	3/24/92		
		USP 5116964	1992	Capon et al.	5/26/92		
		USP 5225538	1993	Capon et al.	7/6/93		
		USP 5336603	1994	Capon et al.	8/9/94		
		USP 5428130	1995	Capon et al.	6/27/95		
		USP 5455165	1995	Capon et al.	10/3/95		
		USP 5514582	1996	Capon et al.	5/7/96		
		USP 5460811	1995	Goeddel et al.	10/24/95		
		USP 5500362	1996	Robinson et al.	3/19/96		
		USP 5545403	1996	Page et al.	8/13/96		
		USP 5545404	1996	Page et al.	8/13/96		
		USP 5545405	1996	Page et al.	8/13/96		
		USP 5721108	1998	Robinson et al.	2/24/98		
		USP 5876961	1999	Crowe et al.	3/2/99		
		USP 5877293	1999	Adair et al.	3/2/99		
		USP 5985279	1999	Waldmann et al.	11/16/99		
		USP 6120767	2000	Robinson et al.	8/19/00		
		USP 5089397	1992	Kushner et al.	2/12/92		
		USP 5219996	1993	Bodmer et al.	6/15/93		
		USP 6020153	2000	Hardman et al.	2/1/00		

 Examiner PHILIP GAMBER 11/6/01

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

09/495/861

1644

16	Ashford et al., 1993, J. Biol. Chem. 268(5):3260-3267 —
	Baker et al., 1991, Antibodies, Immunoconjugates and Radiopharmaceuticals, 4:799-809 —
	Beatty et al., 1989, Cancer Res. 49:1587-1594. —
	Beatty et al., 1990, Cancer Res. 50:922s-926s. —
	Benjamin et al., 1986, Nature 320:449-451 —
	Bindon et al., 1985, Transplant. 40(5):538-544 —
	Bruggemann et al., 1987, J. Exp. Med. 166(5):1351-1361 —
	Byrn et al., 1990, Nature 344:667-670. —
	Cabilly et al., 1984, PNAS USA 81(11):3273-3277 —
	Cabilly & Riggs, 1985, Gene 40(1):157-161. —
	Cobbold, et al., pp.139-154, in Bone Marrow Purging and Processing and Processing, c.1990 by Alan R. Liss, Inc. —
	Cobbold, 1991, Imm. Letters 29:117-122. —
	Cobbold & Waldmann, 1984, Nature 308(5958):460-462 —
	Cohen et al., 1972, PNAS USA 69(8):2110-2114. —
	Colcher et al., 1989, Cancer Res. 49:1738-1745. —
	Cosimi et al., 1990, Surgery 108(2):406-414. —
	Crowe et al., 1992, Clin. Exp. Immunol. 87:105-110. —
	Curti, 1993, Crit. Rev. in Oncol./Hematol. 14:29-39. —
	Dall'Acqua & Carter, 1998, Curr. Op. In Biotech. 8:443-450 —
	Davis et al., 1990, J. Biol. Chem. 265:10410-10418. —
	Dillman, 1989, Ann. Int. Med. 111:592-600. —
	DiMaggio J. et al., pp.177-203 in Cancer Chemo. & Biol. Resp. Mod. Vol. 11, J. Pinedo et al. (eds.) c. 1990 by Elsevier. —
	De Waele et al., 1988, Eur. J. Biochem. 176:287-295. —
	Duda et al., 1990, J. Surgical Onc. 44:73-77 —
	Dyer et al., 1990, Blood 75:709-714. —
	Dyer et al., 1990, Leukemia & Lymphoma 2:179-193. —
16	Feys et al., 1988, Int. J. Cancer Suppl. 2:26-27. —

Examiner

GAMBER 11/9/01

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

MB	Field et al., 1990, 10th Mtg Euro. Soc. For Ani. Cell Tech., Spier et al., Eds. Pp. 742-744. —
	Fukuda et al., 1989, Blood 73(1):84-89. —
	Geisse et al., 1996, Protein Exp & Pur. 8:271-282. —
	Gillies et al., 1989, Bio/Tech. 7:799-804. —
	Goeddel et al., 1979, Nature 281(5732):544-548. —
	Goeddel et al., 1980, Nuc. Acids Res. 8(18):4057-4074. —
	Goochee & Monica, 1990, Bio/Tech. 8:421-427. —
	Goochee et al., 1991, Bio/Tech. 9:1347-1355. —
	Gorman et al., 1991, PNAS 88:4181-4185. —
	Hale, 1983, Mol. Biol. Med. 1:321-334. —
	Hale, 1990, Excerpt from Progress Report - MRC Wellcome Ther. Antibody Centre. —
	Hale et al., 1985, Br. J. of Haematol. 60(1):41-48. —
	Hale et al., 1988, Lancet 2(8625):1394-1399. —
	Hale et al., 1990, Tissue Antigens 35:118-127. —
	Harabayashi et al., 1991, Mitsubishi Kasei R&D Rev. 5(1):85-91. —
	Harris et al., 1990, Proc. 34 th Oholo Conf, Eilat, Israel pgs. 465-477. —
	Harris et al., 1993, TIBTECH 11:42-44. —
	Haynes, 1983, Nucl. Acids Res. 11:687-706. —
	Hird et al., pp.183-189 in Genes & Cancer, Carner & Sikora (eds.), c.1990 by J. Wiley & Sons.
	Hutzell et al., 1991, Cancer Res. 51:181-189. —
	Joziasse et al., 1999, Subcell Biochem. 32:25-48. —
	Joziasse et al., Eur. J. Biochem., 267:6501-6508 (2000). —
	Kaetzel et al., 1985, PNAS USA 82:7280-7283. —
	Kaetzel et al., 1988, J. Biol. Chem. 263(13):6344-6351. —
	Kagawa et al., 1988, J. Biol. Chem. 263(33):17508-17515. —
	Kaufman et al., 1985, Mol. Cell. Biol. 5(7):1750-1759. —
	Kaufman et al., 1990, Meth. Enzymol. 185:537-566. —
	Kaufman et al., 1986, PNAS USA 83:3136-3140. —
	Khazaeli, Meredith et al., 1990, Abstract Submission, "Pharmacokinetics of Single and Repeated Therapeutic...", 3 rd Ann. Conf. On Radioimmunodetection and Radioimmunotherapy of Cancer. —
	Khazaeli, Plott et al., 1990, Abstract Submission, "Pharmacokinetics of Treatment Doses of Chimera I-131 B72.3 in Colorectal Carcinoma Patients"; 37 th Ann. Mtg. Soc. Of Nuclear Med. —
	Khazaeli et al., 1991, Cancer Res. 51:5461-5466. —
	Khazaeli et al., "Frequent Anti-V Region Immune Response to Mouse B72.3 Monoclonal Antibody", J. Clin. Immunol. (submitted) —
	Klein et al., 1981, PNAS USA 78(1):524-528. —
	Kuzel et al., 1990, Oncol. 4(3):77-84, 89. —

Examiner

Gsmuel 11/9/01

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

09/495/861 11/4/01

<i>Me</i>	Kyle et al., 1989, Ann. Rheum Dis 48(5):428-429, (Abstract).
	Leatherbarrow et al., 1985, Mol. Immunol. 22(4):407-415. —
	Lifely et al., 1995, Glycobiol. 5(3):813-822. —
	Lim et al., 1993, Lancet 341:432-433. —
	LoBuglio et al., Abstract Submission, 3 rd Conf. On Radiodetection and Radioimmunotherapy of Cancer, "Human Immune Response to Chemeric B72.3(γ 4)" —
	LoBuglio & Saleh, 1992, Am. J. Med. Sci. 304(3):214-224. —
	LoBuglio et al., 1989, PNAS USA 86:4220-4224. —
	LoBuglio et al., pp.291-295 in Advances in the Applications of Monoclonal Antibodies in Clinical Oncology, Chapman & Hall (eds.), c. 1991. —
	LoBuglio et al., 1992, Abstract Submission, ASCO Annual Meeting, "Dose Fractionation Trial of ¹³¹ I-Chimera B72.3 In Patients With Metastatic Colon Cancer" —
	LoBuglio et al., 2000, Deposition in Interference 104,532. —
	Lockwood et al., 1993, Lancet 341:1620-1622. —
	Lyons et al., 1990, Protein Eng. 3(8):703-708, —
	Martz, 1998, BancBoston Analyst Report, Healthcare Res. Pgs. 69-86. —
	Mathieson et al., 1990, New England J. of Med. 323(4):250-254, —
	Meredith et al., 1990, Abstract Submission 5 th Congress of World Federation of Nuclear Biology and Medicine, "Diagnostic and Therapeutic Doses of Radiolabeled Mouse/Human Chimeric Monoclonal Antibodies". —
	Meredith et al., 1990, Abstract Submission, 3 rd Annual Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, "Phase I Trial of ¹³¹ I-Chimeric Mouse/Human B72.3 (Anti-Tag-72) in Patients with Metastatic Colon Cancer". —
	Meredith et al., 1990, Abstract Submission, Soc. Nucl. Med. 37 th Ann. Meeting, "Body Distribution of Two I-131-Labeled Chimeric Monoclonal Antibodies" —
	Meredith et al., 1991, J. Nuc. Med. 32(6):1162-1168. —
	Meredith et al., 1992, J. Nuc. Med. 33(1):23-29. —
	Meredith, 1990, Protocol: UAC 180 NCI:T89-0144 (NCI/CTEP Sheets) —
	Meredith et al., 1989, Protocol: UAC 180. —
	Meredith et al., 1990, Protocol: UAC 180 (Amended) —
	Meredith et al., 1995, J. Nuc. Med. 36:2229-2233. —
	Meredith et al., Med. Physics "Dosimetry of Solid Tumors" (submitted) —
	Mizouchi et al., 1988, Biochem. J. 254:599-603. —
	Morrison et al., 1984, PNAS USA 81(21): 6851-6855. —
	Morrison et al., 1988, Cancer Invest. 6(2):185-192. —
	Morrison et al., 1988, Clin. Chem. 34(9):1668-1675. —
	Nadler et al., 1980, Cancer Res. 40:3147-3154. —
	Nadler et al., 1980, J. Immunol. 125(2):570-577. —
<i>Me</i>	Nakatani et al., 1989, Bio/Tech. 7:805-810. —

Examiner

Exam 2 11/4/01

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

1/4	Neuberger et al., 1984, Nature 312(5995):604-608. —
	Neuhaus et al., 1989, JACC 14:1566-1569. —
	Neumaier et al., 1990, Cancer Res. 50:2128-2134. —
	Nose & Wigzell, 1983, PNAS USA 80:6632-6635. —
	Oh-eda et al., 1990, J. Biol. Chem. 265(20):11432-11435. —
	Osband et al., 1990, Immunol. Today 11(6):193-195. —
	Page & Sydenham, 1991, Bio/Tech. 9:64-68. —
	Paul, MD (Ed), 1993, "IgG Subclasses" Fundamental Immunol. 3rd Ed. Chap 22, pgs. 838-839. —
	Peakman et al., 1994, Hum. Antibod. Hybrid. 5:65-74. —
	Poynton et al., 1993, Lancet 341:1037. —
	Primus et al., 1990, Cancer Immunol. & Immunother. 31:349-357. —
	Rademacher et al., 1988, Ann. Rev. Biochem. 57:785-838. —
	Raju et al., 1996, Biotechnol. Appl. Biochem. 24:191-194. —
	Raju et al., 2000, Glycobiol. 10(5):477-486. —
	Rhodes, 1988, Adv. Anim. Cell. Biol. Technol. Bioprocess 472-474. —
	Rhodes & Birch, 1988, Bio/Tech. 6:518-523. —
	Riechmann et al., 1988, J. Mol. Biol. 203(3):825-828. —
	Riechmann et al., 1988, Nature 332(6162):323-327. —
	Routledge et al., 1991, Eur. J. Immunol. 21:2717-2725. —
	Ruker et al., 1991, Ann. NY Acad. Of Sci. Recom. DNA Tech. I 646:212-219. —
	Schlom et al., 1980, PNAS USA 77(11):6841-6845. —
	Seaver, 1994, Genetic Eng. News 14(14):10, 21. —
	Sekigawa et al., 1990, J. Virology 64:5194-5198. —
	Shively, Declaration of October 30, 2000
	Shively, Deposition Transcript Interference 104,532. —
	Smith et al., 1990, J. Biol. Chem. 265(11):6225-6234. —
	Spellman et al., 1989, J. Biol. Chem. 264:14100-14111. —
	Stevenson et al., 1989, Anti-Cancer Drug Des. 3:219-230. —
	Stevenson et al., 1991, Blood 77:1071-1079. —
	Takeuchi et al., 1988, J. Biol. Chem. 263:3657-3663. —
	Urlab & Chasin, 1980, PNAS USA 77:4216-4220. —
	van Nagell et al., 1980, Cancer Res. 40(3):502-506. —
	Vandamme et al., 1990, Eur. J. Biochem. 192:767-775. —
	Waldmann, 1991, Science 252:1657-1662. —
	Waldmann, 2000, Ann. Oncol. 11(Suppl. 1(3)):101-106. —
	Waldmann & Goldman, 1989, Am. J. Kidney Dis. 14(5)(Suppl. 2):45-53. —
	Waldmann et al., 1984, Lancet 2(8401):483-486. —

Examiner

GAMDEL

11/9/01

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

[illegible]**Examiner**

Gronberg 11/9/01

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.